TATEVIK MIKAELYAN: Open Payments
NPI 1881095925 · BETHESDA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,033 in 143 payments from 20 companies in 2025. Trend: 2023 $2,161 · 2024 $2,460 · 2025 $3,033
Food & beverage: $3,032Education: $1
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $483 |
| Axsome Therapeutics, Inc. | 17 | $398 |
| AstraZeneca Pharmaceuticals LP | 14 | $381 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $337 |
| Novo Nordisk Inc | 13 | $306 |
| Lundbeck LLC | 12 | $228 |
| PFIZER INC. | 10 | $176 |
| Otsuka America Pharmaceutical, Inc. | 8 | $170 |
| Lilly USA, LLC | 6 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $103 |
Products named: REXULTI, TRINTELLIX, QULIPTA, Symbravo, VRAYLAR, Auvelity, AIRSUPRA, UBRELVY.
Industry payments across MD — which companies pay providers there.
